{"id":"placebo-to-tocilizumab","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Infection (including serious infections)"},{"rate":"10-15","effect":"Upper respiratory tract infection"},{"rate":"5-10","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"5-10","effect":"Hyperlipidemia"},{"rate":"2-5","effect":"Neutropenia"},{"rate":"<1","effect":"Gastrointestinal perforation"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo to tocilizumab","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:01:43.025601+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:01:54.903323+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo to tocilizumab","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:01:55.654894+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-6 receptor alpha subunit inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:01:56.448956+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1237022/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:01:56.357229+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tocilizumab binds to both soluble and membrane-bound IL-6 receptors, preventing IL-6 from activating immune cells and reducing systemic inflammation. This mechanism suppresses the production of inflammatory cytokines and acute phase reactants, making it effective in conditions driven by IL-6-mediated inflammation such as rheumatoid arthritis and cytokine release syndrome.","oneSentence":"Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory IL-6 signaling pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:14.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:01:58.392111+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Rheumatoid arthritis (moderate to severe)"},{"name":"Giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic sclerosis-associated interstitial lung disease"},{"name":"Cytokine release syndrome (CAR-T cell induced)"}]},"trialDetails":[{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT04412772","phase":"PHASE3","title":"Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-06-12","conditions":"COVID-19","enrollment":20},{"nctId":"NCT01782235","phase":"PHASE2, PHASE3","title":"Efficacy of Tocilizumab in Primary Sjögren's Syndrome.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2013-07-24","conditions":"Primary Sjögren's Syndrome (pSS)","enrollment":110},{"nctId":"NCT07254637","phase":"PHASE2","title":"Tocilizumab in Chronic Inflammatory CPPD Disease","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Calcium Pyrophosphate Deposition Disease","enrollment":80},{"nctId":"NCT07263776","phase":"PHASE3","title":"Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-12-05","conditions":"Acute Ischemic Stroke","enrollment":692},{"nctId":"NCT03787290","phase":"PHASE2","title":"Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder","status":"SUSPENDED","sponsor":"Massachusetts General Hospital","startDate":"2026-12-01","conditions":"Major Depressive Disorder","enrollment":35},{"nctId":"NCT01791842","phase":"PHASE2","title":"TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-05-05","conditions":"Fibrous Dysplasia of Bone","enrollment":19},{"nctId":"NCT06726096","phase":"PHASE3","title":"Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing VDJBio Co., LTD.","startDate":"2025-04-09","conditions":"Rheumatoid Arthritis (RA), Anti IL-6R","enrollment":615},{"nctId":"NCT05957107","phase":"PHASE2","title":"Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Beijing VDJBio Co., LTD.","startDate":"2022-05-26","conditions":"Rheumatoid Arthritis","enrollment":181},{"nctId":"NCT07052058","phase":"PHASE2","title":"Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2025-08-25","conditions":"Treatment-Resistant Major Depressive Disorder","enrollment":32},{"nctId":"NCT04888221","phase":"PHASE3","title":"Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-24","conditions":"Giant Cell Arteritis, Neurovascular Disorder","enrollment":66},{"nctId":"NCT05168475","phase":"PHASE2","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-07-14","conditions":"Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome","enrollment":22},{"nctId":"NCT06624436","phase":"PHASE4","title":"Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-10-24","conditions":"Sepsis, Neuroinflammatory Response, Immunosuppresion","enrollment":52},{"nctId":"NCT06818266","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04","conditions":"Sickle Cell Disease, Acute Chest Syndrome","enrollment":130},{"nctId":"NCT02049437","phase":"PHASE1, PHASE2","title":"AIDS 347: IL-6 Blockade in Treated HIV Infection","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2014-08","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT06426160","phase":"PHASE2","title":"Tocilizumab for Painful Chronic Pancreatitis","status":"RECRUITING","sponsor":"Soren Schou Olesen","startDate":"2024-05-21","conditions":"Pancreatitis, Chronic","enrollment":36},{"nctId":"NCT05623592","phase":"PHASE2","title":"Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Bonn","startDate":"2022-11-23","conditions":"Giant Cell Arteritis","enrollment":52},{"nctId":"NCT02901496","phase":"NA","title":"Ectopic Adipose Tissue, Exercise Training and IL-6","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2016-08","conditions":"Adiposity","enrollment":83},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT05407597","phase":"PHASE2, PHASE3","title":"Inhibition of Bradykinin in COVID-19 Infection With Icatibant","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2022-05-16","conditions":"SARS CoV 2 Infection","enrollment":32},{"nctId":"NCT04372186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2020-05-14","conditions":"COVID-19 Pneumonia","enrollment":377},{"nctId":"NCT05349149","phase":"NA","title":"IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout","status":"COMPLETED","sponsor":"Helga Ellingsgaard","startDate":"2022-04-20","conditions":"Glycogen Depletion","enrollment":30},{"nctId":"NCT04687540","phase":"NA","title":"Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2021-04-09","conditions":"Obesity, Healthy","enrollment":25},{"nctId":"NCT04409262","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-06-16","conditions":"COVID-19 Pneumonia","enrollment":649},{"nctId":"NCT02293837","phase":"PHASE2","title":"Tocilizumab (TCZ) in New-onset Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-03-12","conditions":"Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM","enrollment":136},{"nctId":"NCT04356937","phase":"PHASE3","title":"Efficacy of Tocilizumab on Patients With COVID-19","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-04-20","conditions":"SARS-CoV 2","enrollment":243},{"nctId":"NCT04320615","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-03","conditions":"COVID-19 Pneumonia","enrollment":452},{"nctId":"NCT02336048","phase":"PHASE1","title":"A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2015-06-26","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":38},{"nctId":"NCT03263715","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-11-24","conditions":"Polymyalgia Rheumatica","enrollment":39},{"nctId":"NCT03446209","phase":"PHASE2","title":"Tocilizumab for the Treatment of Familial Mediterranean Fever","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2018-04-23","conditions":"Familial Mediterranean Fever","enrollment":30},{"nctId":"NCT03967691","phase":"NA","title":"IL-6 Regulation of Substrate Metabolism and Influence of Obesity","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-06-12","conditions":"Obesity, Healthy","enrollment":22},{"nctId":"NCT03863015","phase":"PHASE2","title":"IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest","status":"COMPLETED","sponsor":"Christian Hassager","startDate":"2019-03-04","conditions":"Heart Arrest, Out-Of-Hospital Cardiac Arrest, Systemic Inflammatory Response Syndrome","enrollment":80},{"nctId":"NCT04377750","phase":"PHASE4","title":"The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2020-04-08","conditions":"Covid19 Pneumonia","enrollment":500},{"nctId":"NCT02453256","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-20","conditions":"Systemic Sclerosis","enrollment":212},{"nctId":"NCT01791153","phase":"PHASE3","title":"An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07-22","conditions":"Giant Cell Arteritis","enrollment":251},{"nctId":"NCT02573012","phase":"PHASE4","title":"Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-29","conditions":"Rheumatoid Arthritis","enrollment":314},{"nctId":"NCT02287922","phase":"PHASE2","title":"A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-03","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT02477059","phase":"PHASE3","title":"Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-11-20","conditions":"Hand Osteoarthritis","enrollment":104},{"nctId":"NCT02034474","phase":"PHASE4","title":"Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-02","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":59},{"nctId":"NCT01034397","phase":"PHASE4","title":"A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01855789","phase":"PHASE3","title":"A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-07","conditions":"Rheumatoid Arthritis","enrollment":718},{"nctId":"NCT02419937","phase":"NA","title":"Short-Term Application of Tocilizumab Following Myocardial Infarction","status":"COMPLETED","sponsor":"Keesler Air Force Base Medical Center","startDate":"2015-05","conditions":"Myocardial Infarction","enrollment":28},{"nctId":"NCT00773461","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10-31","conditions":"Rheumatoid Arthritis","enrollment":209},{"nctId":"NCT00535782","phase":"PHASE3","title":"A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10-31","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT00988221","phase":"PHASE3","title":"A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11-30","conditions":"Juvenile Idiopathic Arthritis","enrollment":188},{"nctId":"NCT01007435","phase":"PHASE3","title":"A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Rheumatoid Arthritis","enrollment":1162},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT00106574","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1220},{"nctId":"NCT00106522","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-05","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT01661140","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":427},{"nctId":"NCT01532869","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-03","conditions":"Sclerosis, Systemic","enrollment":87},{"nctId":"NCT00642460","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":112},{"nctId":"NCT01034137","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":317},{"nctId":"NCT01194414","phase":"PHASE3","title":"A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":1262},{"nctId":"NCT01297699","phase":"PHASE3","title":"Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)","status":"COMPLETED","sponsor":"Hospital Clinico Universitario de Santiago","startDate":"2012-03","conditions":"Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy, Thyroid Eye Disease","enrollment":32},{"nctId":"NCT01991990","phase":"PHASE4","title":"A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT01232569","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":656},{"nctId":"NCT01587989","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT01399697","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":261},{"nctId":"NCT00845832","phase":"PHASE2","title":"A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT00977106","phase":"PHASE3","title":"TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":103},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556},{"nctId":"NCT01491074","phase":"PHASE2","title":"Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2011-08","conditions":"Non-ST Elevation Myocardial Infarction","enrollment":120},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96},{"nctId":"NCT00106535","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-01","conditions":"Rheumatoid Arthritis","enrollment":1196},{"nctId":"NCT01209702","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2010-09","conditions":"Spondylitis, Ankylosing","enrollment":306},{"nctId":"NCT01119859","phase":"PHASE4","title":"A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05","conditions":"Rheumatoid Arthritis","enrollment":326},{"nctId":"NCT01209689","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2010-10","conditions":"Spondylitis, Ankylosing","enrollment":113},{"nctId":"NCT01258712","phase":"PHASE3","title":"Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Chugai Pharma Taiwan","startDate":"2010-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":86},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00106548","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":623},{"nctId":"NCT00144521","phase":"PHASE3","title":"Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2004-02","conditions":"Rheumatoid Arthritis","enrollment":127},{"nctId":"NCT00144599","phase":"PHASE3","title":"Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2004-05","conditions":"Systemic Juvenile Idiopathic Arthritis","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1237022"},"_approvalHistory":[],"publicationCount":381,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to tocilizumab","genericName":"Placebo to tocilizumab","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory IL-6 signaling pathway. Used for Rheumatoid arthritis (moderate to severe), Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:01:58.392111+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}